Results 21 to 30 of about 48,974 (212)
Molecular and clinical aspects of HNSCC in the Republic of Moldova
Romanian Journal of Laboratory Medicine, 2023 Introduction: Complex molecular characterization and integrated approaches in the basic research of HNSCC provide new insights into the understanding and treatment of these tumors.
Stratan Valentina +9 more
doaj +1 more source
Autoimmunity, 2023 Lysosomal associated membrane protein 3 (LAMP3) has been reported to be a tumour promoter in multiple cancer types by modulating tumour cell autophagy. However, the potential mechanism of LAMP3 in radio-resistance of head and neck squamous cell carcinoma
Huixiang Lu +5 more
doaj +1 more source
Neoadjuvant chemotherapy in oral cancer: Current status and future possibilities
Cancer Research, Statistics, and Treatment, 2020 Eighty-five percent of oral cavity cancers present as locally advanced disease and are treated with multimodality approach. Patients who can undergo radical resection have the best outcomes, although the overall results are still unsatisfactory ...
Alok Goel, Anshul Singla, Kumar Prabhash
doaj +1 more source
Cancer Biology & Therapy, 2022 In this study, we report a differential response of mitogen-activated protein kinase–kinase (MEK) inhibitor trametinib in 20 head and neck squamous cell carcinoma (HNSCC) patients’ tumor-derived cell cultures.
Myles Vigoda +14 more
doaj +1 more source
NF-Y Subunits Overexpression in HNSCC [PDF]
Cancers, 2021 NF-Y is the CCAAT-binding trimer formed by the histone fold domain (HFD), NF-YB/NF-YC and NF-YA. The CCAAT box is generally prevalent in promoters of “cancer” genes. We reported the overexpression of NF-YA in BRCA, LUAD and LUSC, and of all subunits in HCC. Altered splicing of NF-YA was found in breast and lung cancer.
Eugenia Bezzecchi +6 more
openaire +2 more sources
, 2023 We characterized the immune context in HPV+ and HPV− HNSCC by integrating scRNA-seq and bulk RNA-seq data.
Zhongqiu Wang (14801422)
core +1 more source
Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]
, 2010 The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp +7 more
core +1 more source
In vivo CRISPR screens reveal potent driver mutations in head and neck cancers
Molecular & Cellular Oncology, 2020 We have recently tested the transforming potential of 484 ‘long-tail’ genes, which are recurrently albeit infrequently mutated in head and neck cancers (HNSCC).
Sampath Kumar Loganathan +1 more
doaj +1 more source
Polish Journal of Pathology, 2022 The aim of the study was to compare prognostic potential of PIK3CA mutations and expression of proteins involved in or regulate EGFR/PI3K/Akt/mTOR signaling in HPV16 positive and HPV negative head and neck squamous cell carcinoma (HNSCC) patients.
Anna Janecka-Widła +3 more
doaj +1 more source
OncoImmunology, 2018 The immune environment of primary tumor is associated with the clinical response and benefit of immunotherapy. This study aims to investigate the intratumoral immune profile and its clinical relevance in advanced head and neck squamous cell carcinoma ...
Bangrong Cao +4 more
doaj +1 more source